Predictors of same day discharge after percutaneous coronary interventions.

Objectives: The aim of this study is to identify possible predictors for same day discharge (SDD) after percutaneous coronary interventions (PCI).

Background: Same day discharge after PCI is becoming more and more appealing and patient's selection criteria are being formulated.

Methods: A retrospective analysis was performed in all PCI procedures from January 2013 until December 2015.

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Objectives: The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).

Background: Glycoprotein IIb/IIIa inhibitors are recommended by international guidelines in patients with acute coronary syndromes undergoing PCI. Abciximab is recommended with a higher level of evidence than eptifibatide in patients with STEMI.